S. S. Zamvil and A. J. Slavin, Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm, vol.2, p.62, 2015.

R. Höftberger, M. Sepulveda, T. Armangue, and Y. Blanco, Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease, Mult Scler, vol.21, issue.7, pp.866-74, 2015.

S. Kim, M. R. Woodhall, J. Kim, S. Kim, K. S. Park et al., Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS, Neurol Neuroimmunol Neuroinflamm, vol.2, issue.6, p.163, 2015.

V. A. Lennon, D. M. Wingerchuk, T. J. Kryzer, and S. J. Pittock, A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis, Lancet, vol.364, issue.9451, pp.2106-2118, 2004.

R. M. Papais-alvarenga, C. Vasconcelos, A. Carra, and I. S. De-castillo, Central Nervous System Idiopathic Inflammatory Demyelinating Disorders in South Americans: A Descriptive, Multicenter, Cross-Sectional Study, PLoS ONE, vol.10, issue.7, p.127757, 2015.

S. Jarius, K. Ruprecht, I. Kleiter, N. Borisow, and N. Asgari, MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and longterm outcome, J Neuroinflammation, vol.13, issue.1, p.280, 2016.

N. Collongues, R. Marignier, H. Zéphir, and C. Papeix, Long-term follow-up of neuromyelitis optica with a pediatric onset, Neurology, vol.75, issue.12, pp.1084-1092, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00617751

M. Reindl and K. Rostasy, MOG antibody-associated diseases, Neurol Neuroimmunol Neuroinflamm, vol.2, issue.1, p.60, 2015.

S. Jarius, K. Ruprecht, B. Wildemann, T. Kuempfel, M. Ringelstein et al., Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients, J Neuroinflammation, vol.9, p.14, 2012.

S. Saadoun, P. Waters, G. P. Owens, J. L. Bennett, A. Vincent et al., Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain, Acta Neuropathol Commun, vol.2, p.35, 2014.

E. Martinez-hernandez, M. Sepulveda, K. Rostásy, R. Höftberger, and F. Graus, Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor ?1 subunit in patients with isolated optic neuritis, JAMA Neurol, vol.72, issue.2, pp.187-93, 2015.

C. F. Lucchinetti, R. N. Mandler, D. Mcgavern, W. Bruck, G. Gleich et al., A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica, Brain, vol.125, pp.1450-61, 2002.

S. Mader, V. Gredler, K. Schanda, K. Rostasy, I. Dujmovic et al., Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders, J Neuroinflammation, vol.8, p.184, 2011.

S. Jarius, I. Kleiter, K. Ruprecht, N. Asgari, K. Pitarokoili et al., MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement -frequency, presentation and outcome, J Neuroinflammation, vol.13, issue.1, p.281, 2016.

J. L. Bennett, J. De-seze, L. , M. Palace, J. Waldman et al., Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography, Mult Scler, vol.21, issue.6, pp.678-88, 2015.

S. Jarius, B. Wildemann, and F. Paul, Neuromyelitis optica: clinical features, immunopathogenesis and treatment, Clin Exp Immunol, vol.176, issue.2, pp.149-64, 2014.

K. Chalmoukou, H. Alexopoulos, S. Akrivou, P. Stathopoulos, M. Reindl et al., Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis, Neurol Neuroimmunol Neuroinflamm, vol.2, issue.4, p.131, 2015.

S. Ramanathan, S. W. Reddel, A. Henderson, J. Parratt, M. Barnett et al., Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis, Neurol Neuroimmunol Neuroinflamm, vol.1, issue.4, p.40, 2014.

F. Schmidt, H. Zimmermann, J. Mikolajczak, F. C. Oertel, F. Pache et al., Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders, Mult Scler Relat Disord, vol.11, pp.45-50, 2017.

E. P. Flanagan, B. G. Weinshenker, K. N. Krecke, V. A. Lennon, C. F. Lucchinetti et al., Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders, JAMA Neurol, vol.72, issue.1, pp.81-88, 2015.

D. M. Wingerchuk, B. Banwell, J. L. Bennett, P. Cabre, W. Carroll et al., International consensus diagnostic criteria for neuromyelitis optica spectrum disorders, Neurology, vol.85, issue.2, pp.177-89, 2015.

D. M. Wingerchuk, V. A. Lennon, C. F. Lucchinetti, S. J. Pittock, and B. G. Weinshenker, The spectrum of neuromyelitis optica, Lancet Neurol, vol.6, issue.9, pp.805-820, 2007.

S. Jarius and B. Wildemann, Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature, Brain Pathol, vol.23, issue.6, pp.661-83, 2013.

T. Akaishi, D. K. Sato, I. Nakashima, T. Takeshita, T. Takahashi et al., MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study, J Neurol Neurosurg Psychiatr, vol.87, issue.4, pp.446-454, 2016.

B. G. Weinshenker and D. M. Wingerchuk, Neuromyelitis Spectrum Disorders, Mayo Clin Proc, vol.92, issue.4, pp.663-79, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02065598

V. A. Lennon, T. J. Kryzer, S. J. Pittock, A. S. Verkman, and S. R. Hinson, IgG marker of opticspinal multiple sclerosis binds to the aquaporin-4 water channel, J Exp Med, vol.202, issue.4, pp.473-480, 2005.

E. S. Sotirchos, S. Saidha, G. Byraiah, M. A. Mealy, M. A. Ibrahim et al., In vivo identification of morphologic retinal abnormalities in neuromyelitis optica, Neurology, vol.80, issue.15, pp.1406-1420, 2009.

S. Jarius, K. Ruprecht, I. Kleiter, N. Borisow, N. Asgari et al., MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin, J Neuroinflammation, vol.13, issue.1, p.279, 2016.

D. M. Wingerchuk, B. Banwell, J. L. Bennett, P. Cabre, and C. W. , International consensus diagnostic criteria for neuromyelitis optica spectrum disorders, Neurology, vol.14, issue.2, pp.177-89, 2015.

E. Schneider, H. Zimmermann, T. Oberwahrenbrock, F. Kaufhold, E. M. Kadas et al., Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis, PLoS ONE, vol.8, issue.6, p.66151, 2013.

J. N. Ratchford, M. E. Quigg, A. Conger, T. Frohman, E. Frohman et al., Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies, Neurology, vol.73, issue.4, pp.302-310, 2009.

S. L. Galetta, P. Villoslada, N. Levin, K. Shindler, H. Ishikawa et al., Acute optic neuritis: Unmet clinical needs and model for new therapies, Neurol Neuroimmunol Neuroinflamm, vol.2, issue.4, p.135, 2015.

C. Trebst, S. Jarius, A. Berthele, F. Paul, S. Schippling et al., Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS), J Neurol, vol.261, issue.1, pp.1-16, 2014.

D. L. Budenz, D. R. Anderson, R. Varma, J. Schuman, L. Cantor et al., Determinants of Normal Retinal Nerve Fiber Layer Thickness Measured by Stratus OCT, Ophthalmology, 2007.

D. K. Sato, D. Callegaro, L. , M. A. Waters, P. J. De-haidar-jorge et al., Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders, Neurology, vol.82, issue.6, pp.474-81, 2014.

F. Pache, H. Zimmermann, J. Mikolajczak, S. Schumacher, A. Lacheta et al., MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgGseropositive versus AQP4-IgG-seropositive patients, J Neuroinflammation, vol.13, issue.1, p.282, 2016.

K. Ikeda, N. Kiyota, H. Kuroda, D. K. Sato, S. Nishiyama et al., Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody, Mult Scler, 2015.

J. Kitley, P. Waters, M. Woodhall, M. I. Leite, A. Murchison et al., Neuromyelitis optica spectrum disorders with aquaporin-4 and myelinoligodendrocyte glycoprotein antibodies: a comparative study, JAMA Neurol, vol.71, issue.3, pp.276-83, 2014.

S. Jarius, K. Ruprecht, I. Kleiter, N. Borisow, N. Asgari et al., MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome, J Neuroinflammation, vol.13, issue.1, p.280, 2016.

N. Collongues, R. Marignier, H. Zéphir, C. Papeix, B. Fontaine et al., Longterm follow-up of neuromyelitis optica with a pediatric onset, Neurology, vol.75, issue.12, pp.1084-1092, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00617751